May 22, 2020 -- Nautilus Biotechnology announced that it has raised $76 million to develop a single-molecule sensitivity proteomics platform. The funding efforts were led by Vulcan Capital, an investment firm founded by Microsoft co-founder Paul Allen.
The company will use the funds to develop technologies that enable a deeper, richer understanding of proteins and to expand scientific and engineering staff across a wide variety of levels and disciplines. The proprietary proteomics platform will bring increased resolution of the human proteome, according to Nautilus.
In addition to Vulcan, Perceptive Advisors, Bezos Expeditions, and Defy Partners were new investors in the series B offering. Previous investors included AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group.